Home/ Stocks/ NKTX

Nkarta, Inc. Common Stock

NKTX XNAS

$2.41 +0.12 (+5.24%) ▲ 15-min delayed

Open

$2.35

High

$2.44

Low

$2.32

Volume

531.2K

Market Cap

$163.84M

About Nkarta, Inc. Common Stock

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 108 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-27,832,000	$-0.37
FY 2025	$0	$-104,084,000	$-1.41
Q3 2025	$0	$-21,715,000	$-0.29
Q2 2025	$0	$-22,977,000	$-0.31

Related Market News

No specific coverage for NKTX yet. Check out our latest market news or earnings calendar.

Get NKTX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Nkarta, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.